Fabienne Hermitte, Ph.D., brings deep expertise in clinical diagnostics to her role at Veracyte. She cofounded HalioDx, an immuno-oncology diagnostics company, in 2015. At HalioDx, she led the Regulatory, Quality, Medical Affairs, Clinical Development and Diagnostic Marketing teams prior to the company’s acquisition by Veracyte in August 2021.
Prior to HalioDx, Dr. Hermitte, a molecular biologist, cofounded Ipsogen in 1999, where she led the development and international registrations of more than 80 molecular diagnostic products for the diagnosis and disease monitoring of leukemias. When Ipsogen was acquired by Qiagen in 2011, she joined the Qiagen Development & Regulatory leadership teams and oversaw the clinical validation and FDA submission of the Ipsogen JAK2V617F molecular diagnostic kit.
Dr. Hermitte holds a Ph.D. in molecular biology and two Masters degrees in Life Science and Health from AgroParisTech and Paris Sud School of Medicine.